Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideto Oshikawa

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Clinical Rheumatology|October 30, 2020
Risk of serious infection, malignancy, or death in Japanese rheumatoid arthritis patients treated with a combination of abatacept and tacrolimus: a retrospective cohort studyKenichiro Tokunaga, Kunihiko Matsui, Hideto Oshikawa, et al.
Rheumatology (Oxford, England)|September 6, 2011
An observational study of tocilizumab and TNF-α inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safetyKazuki Yoshida, Yasuharu Tokuda, Hideto Oshikawa, et al.
Modern Rheumatology|July 4, 2012
Differences in clinical manifestations, treatment, and concordance rates with two major sets of criteria for Behçet's syndrome for patients in the US and Japan: data from a large, three-center cohort studyTatsuo Kobayashi, Mitsumasa Kishimoto, Christopher J Swearingen, et al.
Modern Rheumatology|May 10, 2024
Factors contributing to the improvement in Japanese Health Assessment Questionnaire after 3 years of treatment with abatacept in biologic-naïve rheumatoid arthritis patients: Interim results of a long-term, observational, multicentre study in Japan (ORIGAMI)Kenta Misaki, Eiichi Tanaka, Eisuke Inoue, et al.
Modern Rheumatology|December 11, 2025
Factors associated with treatment discontinuation and age-stratified safety of abatacept in Japanese patients with rheumatoid arthritis: 5-year results of the ORIGAMI studyMasayoshi Harigai, Eiichi Tanaka, Eisuke Inoue, et al.
Modern Rheumatology|December 16, 2021
Effectiveness and safety of subcutaneous abatacept in biologic-naïve RA patients at Week 52: A Japanese multicentre investigational study (ORIGAMI study)Naoto Tamura, Takanori Azuma, Kenta Misaki, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Clinical Rheumatology|October 30, 2020
Risk of serious infection, malignancy, or death in Japanese rheumatoid arthritis patients treated with a combination of abatacept and tacrolimus: a retrospective cohort studyKenichiro Tokunaga, Kunihiko Matsui, Hideto Oshikawa, et al.
Rheumatology (Oxford, England)|September 6, 2011
An observational study of tocilizumab and TNF-α inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safetyKazuki Yoshida, Yasuharu Tokuda, Hideto Oshikawa, et al.
Modern Rheumatology|July 4, 2012
Differences in clinical manifestations, treatment, and concordance rates with two major sets of criteria for Behçet's syndrome for patients in the US and Japan: data from a large, three-center cohort studyTatsuo Kobayashi, Mitsumasa Kishimoto, Christopher J Swearingen, et al.
Modern Rheumatology|May 10, 2024
Factors contributing to the improvement in Japanese Health Assessment Questionnaire after 3 years of treatment with abatacept in biologic-naïve rheumatoid arthritis patients: Interim results of a long-term, observational, multicentre study in Japan (ORIGAMI)Kenta Misaki, Eiichi Tanaka, Eisuke Inoue, et al.
Modern Rheumatology|December 11, 2025
Factors associated with treatment discontinuation and age-stratified safety of abatacept in Japanese patients with rheumatoid arthritis: 5-year results of the ORIGAMI studyMasayoshi Harigai, Eiichi Tanaka, Eisuke Inoue, et al.
Modern Rheumatology|December 16, 2021
Effectiveness and safety of subcutaneous abatacept in biologic-naïve RA patients at Week 52: A Japanese multicentre investigational study (ORIGAMI study)Naoto Tamura, Takanori Azuma, Kenta Misaki, et al.
Pageof 1